Condition
glp1 Agonist
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Recruiting1
Not Yet Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07224880RecruitingPrimary
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
NCT07175805Not Yet Recruiting
Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy
Showing all 2 trials